A Study of 3 Investigational Products on the Microbiome and Scalp Attributes in Children With Curly Hair

NCT ID: NCT05123911

Last Updated: 2023-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

35 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-11-13

Study Completion Date

2022-03-18

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the topical safety (tolerability/acceptability) of a kit of cosmetic products (shampoo, conditioner, and combing cream), the presence of residues on the scalp through visual assessment and image capture, the skin barrier, pH, and sebum level. All these evaluations will be performed before and after 28 plus minus (+-) 2 days of use under normal conditions, under the supervision of dermatologist and pediatrician.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Product Kit: Shampoo, Conditioner and Combining Cream (Investigational Products [IPs])

The parents/legally acceptable representative (LAR) of the participants will receive a product kit containing the 3 investigational products (shampoo, conditioner and combining cream) and will bathe the child participant with shampoo followed by conditioner and then apply combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.

Group Type EXPERIMENTAL

Investigational Shampoo

Intervention Type OTHER

Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.

Investigational Conditioner

Intervention Type OTHER

Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.

Investigational Combing Cream

Intervention Type OTHER

Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Investigational Shampoo

Parent/LAR will bathe the child participant with the investigational shampoo at least 3 times a week for up to 28 days.

Intervention Type OTHER

Investigational Conditioner

Parent/LAR will bathe the child participant with the investigational conditioner at least 3 times a week for up to 28 days.

Intervention Type OTHER

Investigational Combing Cream

Parent/LAR will apply investigational combining cream to wet and previously moistened hair at least 3 times a week for up to 28 days.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

For children

* Female and male children participants
* 3 to 6 years old
* Fitzpatrick Skin Type IV to VI
* Generally, in good health based on medical history reported by the parent/legally acceptable representative (LAR)
* Intact skin in the test region, scalp, (except for the presence of mild seborrheic dermatitis, if applicable)
* Children participants with curly to kinky hair
* Children participants with a minimum hair length of 5 cm (3 fingers)
* Minors under the age of assent should be accompanied by a LAR who can read, write, speak, and understand Portuguese

For parent/LAR of participants

* 18 to 65 years old
* Generally, in good health based on medical history
* Has presented proof of guardianship for the infant participant (that is, birth certificate along with valid Identity document \[ID\] of parents/LAR)
* Able to read, write, speak, and understand Portuguese
* Individual has signed the informed consent document (ICD) and ICID (Informed consent image document)
* Be willing and able to participate and comply with the study that requires the use of the principal investigator (PIs) as indicated on the child throughout the study period
* Agrees not to use the provided products on any other family member (other than the child participant) for the duration of the study
* Agrees to bathe your child in the shower instead of the bathtub
* Intends to complete the study and is willing and able to follow all study instructions

Exclusion Criteria

For Children

* Has known allergies or adverse reactions to common topical skincare products, including shampoo, conditioner and combing cream
* Presents with a skin condition that may confound the study results (specifically psoriasis, eczema, atopic dermatitis, cutaneous xerosis, erythema or active skin cancer)
* Presents with primary/secondary lesions (example: scars, ulcers, vesicles) on test sites
* Has parent/LAR reported Type 1 or Type 2 diabetes in the participant or is taking insulin or another anti-diabetic medication
* Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including: a) Immunosuppressive or steroidal drugs within 2 months before Visit 1; b) Non-steroidal anti-inflammatory drugs within 5 days before Visit 1; c) Antihistamines within 2 weeks before Visit 1; d) Topical or systemic antibiotics or antifungals within 30 days before Visit 1
* Has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study
* Having had chemical treatments that transform the hair shaft (for example: straightening, hair relaxation, Et cetera \[etc.\])
* Present folliculitis and/or hair loss disorders
* Use anti-hair loss treatment for at least three months before the study start
* Use anti-dandruff shampoos on the scalp and/or hair for at least three weeks before the study start
* Be using or have used in the last 4 weeks long hairstyles, such as Nago braids made only on natural hair or with the addition of synthetic fiber threads (example: Kanekalon, Jumbo or wool)
* Exposure or having been exposed in the last 7 days to the beach, swimming pool and intense sun during the study period
* Simultaneously participating in any other clinical study
* Be an immediate family member of the PI, Study Site, or Sponsor
* Initiate probiotic treatment or supplementation (Culturelle, Provance, Colidis, Probioatop, Bifidobacterium, Lactobacillus, etc.) during the study
* Change treatment with probiotics (Culturelle, Provance, Colidis, Probioatop, Bifidobacterium, Lactobacillus, etc.) if the participating child is already using them before the study begins

For parent/LAR of participants

* Has known allergies or adverse reactions to common topical skincare products, including shampoo, conditioner and combing cream
* Has reported Type 1 or Type 2 diabetes or is taking insulin or another anti-diabetic medication
* Is taking a medication that would mask an Adverse Event (AE) or confound the study results, including: a) Immunosuppressive or steroidal drugs within 2 months before Visit 1; b) Non-steroidal anti-inflammatory drugs within 5 days before Visit 1; c) Antihistamines within 2 weeks before Visit 1
* Is self-reported to be pregnant or planning to become pregnant during the study
* Has a history of or a concurrent health/other condition/situation which may put the individual at significant risk, confound the study results, or interfere significantly with the individual's participation in the study
* Is simultaneously participating in any other clinical study
* Is an employee/contractor or immediate family member of the PI, study site, or sponsor


* History of a confirmed COVID-19 infection in the last 30 days
* Contact with COVID-19-infected person within 14 days prior to enrollment
* Any international travel within 14 days prior to enrollment including members in the same household
* Participants with self-reported symptoms within the past 2 weeks: a) Unexplained cough, shortness of breath/difficulty breathing, fatigue, body aches (headaches, muscle pain, stomachaches), conjunctivitis, loss of smell, loss of taste, poor appetite, nausea, vomiting, diarrhea, palpitations, fever, or chest pain/tightness; b) Temperature greater than or equal to (\>=) 38 degree Celsius (°C)/100 degree Fahrenheit (°F), measured; c) Use of fever reducers within 2 days prior to each on-site visit
Minimum Eligible Age

3 Years

Maximum Eligible Age

6 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Johnson & Johnson Consumer Inc. (J&JCI)

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mariane M Mosca, Bsc

Role: PRINCIPAL_INVESTIGATOR

Allergisa Pesquisa Dermato-Cosmética Ltda

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Allergisa Pesquisa Dermato-Cosmética LTDA

Campinas, São Paulo, Brazil

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Brazil

References

Explore related publications, articles, or registry entries linked to this study.

Agência Nacional De Vigilância Sanitária. Guia para Avaliação de Segurança de Produtos Cosméticos. 2a ed., 2012. Available on <http://www.anvisa.gov.br/cosmeticos/guia/guia_cosmeticos_final_2.pdf> Accessed by: 05 Jan 2017

Reference Type BACKGROUND

ASSOCIAÇÃO MÉDICA MUNDIAL. Declaração de Helsinque. Princípios Éticos para Pesquisa Médica Envolvendo Participantes Humanos. Available on: <http://www.wma.net/en/30publications/10policies/b3/17c.pdf>. Accessed by: 05 Jan 2017.

Reference Type BACKGROUND

BRASIL. Ministério da Saúde. RDC nº 466, de 12 de dezembro 2012. Aprova diretrizes e normas regulamentadoras de pesquisas envolvendo seres humanos. Available on: <http://conselho.saude.gov.br/resolucoes/2012/Reso466.pdf>. Accessed by: 05 Jan 2017.

Reference Type BACKGROUND

Cortex Technology. DermaLab® Combo - technical specifications. Available on: https://cortex.dk/multi-parameter-dermalab-combo/.

Reference Type BACKGROUND

Courage + Khazaka electronic GmbH. Skin-pH-Meter PH 905: The Measuring Principle. Available on: <http://www.courage-khazaka.de/index.php/en/artikel-work/59-products/scientific/132-skinphmeter.

Reference Type BACKGROUND

Courage + Khazaka electronic GmbH. Sebumeter® SM 815. The Measuring Principle. Available on: https://courage-khazaka.de/en/scientific-products/efficacy-tests/16-wissenschaftliche-produkte/alle-produkte/151-sebumeter-e.

Reference Type BACKGROUND

Courage + Khazaka electronic GmbH. Tewameter® TM Nano. The Measuring Principle. Available on: https://courage-khazaka.de/en/scientific-products/efficacy-tests/16-wissenschaftliche-produkte/alle-produkte/157-tewameter-nano-e.

Reference Type BACKGROUND

De la Mettrie R, Saint-Leger D, Loussouarn G, Garcel A, Porter C, Langaney A. Shape variability and classification of human hair: a worldwide approach. Hum Biol. 2007 Jun;79(3):265-81. doi: 10.1353/hub.2007.0045.

Reference Type BACKGROUND
PMID: 18078200 (View on PubMed)

International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use.. ICH harmonized tripartite guideline: Guideline for Good Clinical Practice. J Postgrad Med. 2001 Jan-Mar;47(1):45-50. No abstract available.

Reference Type BACKGROUND
PMID: 11590294 (View on PubMed)

OPAS. Organização Pan-Americana de Saúde. Boas Práticas Clínicas: Documento das Américas. IV Conferência Pan-Americana para Harmonização da Regulamentação Farmacêutica, 2005. Disponível em: http://www.anvisa.gov.br/medicamentos/pesquisa/boaspraticas_americas.pdf Acesso em: 10 18 MAR ABR 2016.

Reference Type BACKGROUND

Saxena R, Mittal P, Clavaud C, Dhakan DB, Roy N, Breton L, Misra N, Sharma VK. Longitudinal study of the scalp microbiome suggests coconut oil to enrich healthy scalp commensals. Sci Rep. 2021 Mar 31;11(1):7220. doi: 10.1038/s41598-021-86454-1.

Reference Type BACKGROUND
PMID: 33790324 (View on PubMed)

Oliveira, A. C. S. TRANÇANDO CABELO, IDENTIDADE, ESTIGMA E CONSUMO: um estudo sobre as maneiras de consumir relacionadas à manipulação capilar de mulheres de cabelos crespos e cacheados a partir da teoria da prática. Dissertação (mestrado) - Universidade Federal de Minas Gerais, Centro de Pós-Graduação e Pesquisas em Administração (2019). Disponível em: https://repositorio.ufmg.br/bitstream/1843/30441/1/Disserta%C3%A7%C3%A3o_finalizada%20-%20Ana%20Carolina%20Soares.pdf. Acesso em: 17 SET 2021.

Reference Type BACKGROUND

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CCSSKB004136

Identifier Type: OTHER

Identifier Source: secondary_id

CCSSKB004136

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.